Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients

Kit Lam, D. S. Alberts, Y. M. Peng, F. Brodar, B. Matias, M. Modiano, R. Tuttle, V. Sol Lucas, W. Wargin

Research output: Contribution to journalArticle

Abstract

502U83, a novel arylmethylaminopropanediol, has proven active in vivo against a panel of murine leukemia and solid tumors as well as in a tumor clonogenic assay against a variety of fresh human cancers. A total of 35 previously treated cancer patients were enrolled in a phase I study of this compound. The maximally tolerated dose (MTD) appears to be 12800 mg/m2/72 h by continuous intravenous infusion with severe granulocytopenia occurring in three of five patients. There were no objective clinical responses. Serum pharmacokinetic parameters were as follows: plasma terminal phase half-life (t( 1/2 )β) = 3.84 h; total body clearance (CL(B)) = 53.1 l/h/m2; volume of distribution at steady state (V(dss)) = 127.9 l/m2; maximum plasma concentration (C(max)) = 3.7 μg/ml (at 12800 mg/m2/72 h dose).

Original languageEnglish (US)
Pages (from-to)219-224
Number of pages6
JournalAnti-Cancer Drugs
Volume3
Issue number3
StatePublished - 1992
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Lam, K., Alberts, D. S., Peng, Y. M., Brodar, F., Matias, B., Modiano, M., Tuttle, R., Sol Lucas, V., & Wargin, W. (1992). Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients. Anti-Cancer Drugs, 3(3), 219-224.